Chardan Capital Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price

Iovance Biotherapeutics (NASDAQ:IOVA) had its price target dropped by research analysts at Chardan Capital from $17.00 to $16.00 in a research note issued to investors on Wednesday,MarketScreener reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target indicates a potential upside of 322.16% from the company’s current price.

IOVA has been the subject of a number of other research reports. Citizens Jmp upgraded shares of Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Wednesday. The Goldman Sachs Group restated a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Barclays upped their price target on Iovance Biotherapeutics from $9.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Finally, HC Wainwright dropped their price objective on Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

Iovance Biotherapeutics Trading Down 1.0%

Iovance Biotherapeutics stock opened at $3.79 on Wednesday. The firm has a market cap of $1.56 billion, a PE ratio of -3.38 and a beta of 0.76. Iovance Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $5.64. The stock’s 50 day simple moving average is $2.69 and its two-hundred day simple moving average is $2.42.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The firm had revenue of $86.77 million during the quarter, compared to analyst estimates of $81.61 million. On average, equities research analysts forecast that Iovance Biotherapeutics will post -1.24 EPS for the current year.

Institutional Trading of Iovance Biotherapeutics

Several large investors have recently made changes to their positions in the company. Xponance LLC lifted its holdings in Iovance Biotherapeutics by 19.4% in the 4th quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 3,950 shares in the last quarter. Raymond James Financial Inc. grew its holdings in shares of Iovance Biotherapeutics by 1.4% during the second quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock worth $557,000 after buying an additional 4,618 shares in the last quarter. R Squared Ltd raised its position in shares of Iovance Biotherapeutics by 41.4% in the third quarter. R Squared Ltd now owns 16,043 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 4,700 shares during the last quarter. Orion Investment Co lifted its stake in shares of Iovance Biotherapeutics by 0.3% in the fourth quarter. Orion Investment Co now owns 1,856,934 shares of the biotechnology company’s stock worth $5,069,000 after buying an additional 5,150 shares in the last quarter. Finally, Flputnam Investment Management Co. lifted its stake in shares of Iovance Biotherapeutics by 35.4% in the third quarter. Flputnam Investment Management Co. now owns 20,289 shares of the biotechnology company’s stock worth $44,000 after buying an additional 5,300 shares in the last quarter. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Reported strong Q4 and FY2025 results: 61% year‑over‑year revenue growth to $264M and Q4 product revenue of roughly $87M; Q4 EPS loss was narrower than expected and revenue beat consensus — this underpins the recent rally. Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success
• Positive Sentiment: Amtagvi (lifileucel) is now an approved commercial product with accelerating adoption — company reported product sales growth (sales up ~30–33% in Q4) and lifileucel has received Fast Track designation in second‑line NSCLC; management plans registrational sarcoma studies after strong early responses. This shifts Iovance toward execution and revenue growth rather than a pure pipeline bet. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test
• Positive Sentiment: Encouraging sarcoma data and 50% ORR in early cohorts prompted plans for a registrational sarcoma trial — clinical validation of TIL therapy in new indications supports upside to revenue and long‑term value. Iovance Announces Positive Results for TIL in Soft Tissue Sarcomas
• Positive Sentiment: Analysts updated models and ratings after the print — Barclays raised its target and kept an overweight stance; HC Wainwright raised FY2026/27 estimates and maintains a Buy with a higher target, and other firms issued buy/outperform notes — analyst support likely amplified buying. Analyst Coverage Changes
• Positive Sentiment: Operational story: coverage highlighting the Philadelphia manufacturing/scale‑up helps explain the stock’s multi‑week surge — investors are pricing in improved capacity to supply Amtagvi. Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
• Neutral Sentiment: Management scheduled investor presentations at TD Cowen and Barclays conferences in early March — useful for more detail but not immediate catalysts. Iovance to Present at Upcoming Conferences
• Neutral Sentiment: Unusually large options volume and heavy intraday trading indicate speculative positioning and rapid repricing; this raises liquidity but not a directional fundamental change. Options Volume Report
• Negative Sentiment: Short interest ballooned (~36.9% of float, short‑interest ratio ~14.6 days) — while this can fuel squeezes on rallies, it also increases downside pressure and volatility when momentum fades or profit taking occurs.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.